Articles tagged with Melanoma Cells
Researchers have identified a unique odor signature associated with melanoma cells, which can be used to detect the deadliest form of skin cancer. A nanotechnology-based sensor also demonstrated reliable differentiation between melanoma cells and normal skin cells.
Researchers at The Wistar Institute have discovered a way to overcome drug resistance in melanoma by combining anticancer therapies with diabetes drugs. By sensitizing resistant cells, the combined therapy can destroy a subset of drug-resistant cells within a tumor.
Scientists developed a potential new drug that destroys cancer cells while preventing their spread to other sites in the body. The compound was tested in laboratory mice and showed promising results.
Scientists have discovered a mechanism to reactivate the tumor suppressor p53 in metastatic melanoma cells, which were previously silenced by proteins iASPP and MDM2. Treatment with a combination of small molecules JNJ-7706621 and Nutlin-3 restored p53 function and suppressed tumor growth in mice.
Navin Varadarajan will study adoptive cell therapy (ACT) using a special polymer slide called the Nano well array. He aims to identify specific properties of modified TIL cells involved in fighting tumors, helping researchers develop successful new therapies.
Researchers have discovered a virus that can selectively infect and kill human melanoma cells, leaving normal cells unharmed. This breakthrough offers new hope for treating the deadliest form of skin cancer, which has seen a tripling of incidence over three decades.
Gossypin, a naturally-occurring substance, has been shown to inhibit the growth of human melanoma cells and reduce tumor volume in mice. The compound may have great therapeutic potential as a dual inhibitor of mutations that occur in the vast majority of melanoma patients.
Researchers found that Mer receptor overexpression correlates with melanoma progression and aggressiveness, driving disease severity. Investigational drug UNC1062 blocks Mer survival signaling, killing melanoma cells in dishes and mouse models.
Researchers discovered that oncogene-induced senescence can suppress cancer development by depriving cells of nucleotides, the building blocks of DNA. By targeting the RRM2 enzyme, which produces these nucleotides, scientists may be able to stabilize senescence and improve the effectiveness of chemotherapy or targeted drugs.
Researchers at UCLA and Caltech have successfully monitored the change in genetically modified immune cells, showing a promising treatment for melanoma. A new group of non-engineered T cells arose with a similar tumor-killing effect that lasted even longer than the engineered cells.
Researchers found that melanoma cells develop resistance to BRAF inhibitor treatment by shifting to alternative energy production methods. By targeting mitochondrial metabolism, combination treatments may improve the efficacy of current therapies.
A study published in Science Signaling identified a critical protein role in the spread of melanoma to the lungs. Researchers found that inhibiting the adenosine diphosphate ribosylation factor 6 (ARF6) protein reduces melanoma metastasis.
Researchers discovered melanoma tumors deliberately create conditions to knock out the body's 'premier' immune defense and attract a weaker immune response. Higher levels of IgG4 antibodies in patients' blood are linked to a less favorable prognosis.
Researchers at UCLA refine their 'NanoVelcro' device to capture and analyze single cancer cells from patient blood, enabling 'liquid biopsies' for metastatic melanoma. The improved device allows doctors to tailor personalized treatment to specific patients.
Scientists at Queen Mary University of London identified a gene linked to resistance in melanoma tumour cells. The gene TP63 was found to correlate significantly with a worse prognosis in melanoma patients.
Researchers found that melanoma cells can transfer proteins to the immune system, allowing it to gather crucial intelligence and develop cytokines to kill cancer cells. This process, called positive feedback loop, tips the scales in favor of the immune cells.
Scientists successfully regenerate patients' immune cells using stem cell technology, creating long-lived and targeted cells to combat cancer and viral infections. The findings could lead to the development of strategies to rejuvenate exhausted immune responses.
Researchers found that microRNA-26a suppresses melanoma cell growth while leaving healthy cells unharmed. Reintroducing microRNA-26a to melanoma cell lines led to a marked decrease in cancer cell survival, suggesting it as a potential therapeutic target for melanoma treatment.
Researchers at the University of Manchester have discovered a protein that enables cancer cells to resist MEK inhibitors, a common treatment for melanoma. By targeting this protein, SMURF2, with a combination of MEK inhibitors and reduced doses, sensitivity to the drug can be significantly increased.
Researchers at Moffitt Cancer Center have found that blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improves adoptive T-cell therapy for melanoma. This blockade is achieved after total body irradiation eliminates these cells, leading to delayed tumor growth and enhanced survival in mice.
A research team has uncovered the molecular structure of MITF, a master regulator central to melanoma and other diseases. The X-ray analysis revealed unexpected insertions that limit MITF's ability to bind to DNA, providing a rational basis for the development of tailor-made drugs targeting this protein.
Researchers at IRIC discovered a protein, RSK, that contributes to chemoresistance in melanoma. Blocking its action could lead to improved treatment of skin cancers.
Melanoma cells can temporarily alter their external characteristics to become invisible to defense cells, allowing them to evade destruction. This knowledge forms an important foundation for improving combination therapies and may also be relevant to treatment with inhibitors of signal transmission in tumor cells.
Researchers found that B-Raf and C-Raf proteins are crucial for melanocyte stem cell renewal, leading to progressive whitening of fur in mice. The study provides insights into the role of these proteins in cancer development and offers potential new strategies for treating melanoma.
Researchers have discovered that melanoma cells produce receptors for chemokines present in the brain tissue, drawing them to the brain. This interaction could be a potential target for new therapies.
Researchers at UC Irvine's Chao Family Comprehensive Cancer Center have identified a key genetic pathway responsible for melanoma cells' resistance to chemotherapy. Targeting this pathway could lead to the development of new treatments for the deadly skin cancer, which claims nearly 10,000 U.S. lives each year.
Researchers at Brigham and Women's Hospital have discovered a new biomarker for melanoma, a deadly skin cancer. The findings reveal that certain biochemical elements in DNA are absent in melanoma cells, serving as a key indicator for malignant melanoma.
Researchers at the University of Hawaii Cancer Center have identified a germline BAP1 mutation as the cause of a novel cancer syndrome characterized by malignant mesothelioma and various types of melanomas. This discovery provides a visual marker for identifying individuals at high risk, enabling early detection and treatment.
Researchers have identified melanoma stem cells marked by the enzyme ALDH, which exhibit high tumorigenicity and resistance to chemotherapy. Targeting these cells with a new therapy could boost the effectiveness of existing drugs.
A laboratory study reveals that Elesclomol triggers cell death in metastatic melanoma cells by suppressing oxidative phosphorylation. The research also suggests a two-pronged strategy to target both glycolysis and oxidative phosphorylation for effective cancer treatment.
A new channel-forming protein, Panx1, has been identified as a potential target for the treatment of melanoma skin cancer. Over-expression of Panx1 in melanoma cells enables aggressive tumor behavior and metastasis. Researchers suggest targeting this protein with a topical medication to treat melanoma lesions.
A study published in Cancer Research found that immune responses can be activated locally in the tumor microenvironment of melanoma skin metastases, contrary to previous thought. This discovery suggests that ectopic lymphoid structures may play a role in antimelanoma immune responses and has implications for treatment.
Agnieszka Gembarska and Chris Marine discovered a new way to combat melanoma by inhibiting the interaction between MDM4 and p53, restoring tumor suppressive effect in melanoma cells. This approach shows promise for improving clinical response to treatment, particularly when combined with BRAF inhibitors.
Researchers identified six genes with driving mutations in melanoma, three of which have recurrent 'hotspot' mutations caused by UV light exposure. The study provides potential targets for new treatments and offers insights into the frequency and characteristics of driver mutations.
Scientists from the University of Zurich identified a key role for the Sox10 gene in promoting melanoma development and proliferation. Suppressing this gene in mice inhibited cancer growth, offering new potential therapy avenues.
Researchers at Brigham and Women's Hospital have discovered a cell-signaling molecule, interleukin-9, that inhibits melanoma growth in immune cells. High expression of this molecule in TH17 cells provides significant resistance to melanoma tumor growth.
Two experimental drugs targeting the PD-1/PD-L1 pathway showed promising early results in patients with advanced non-small cell lung, melanoma, and kidney cancers. Significant tumor shrinkage was seen in patients treated with these therapies.
Scientists from Ludwig Institute for Cancer Research (LICR) present promising research findings at ASCO. The studies aim to advance the scientific dialogue and potentially lead to new cancer treatments.
Scientists at UTHealth Medical School have made a key discovery in cell signaling relevant to the fight against melanoma skin cancer. They found that BRaf inhibitors, widely used to treat melanomas, can actually enhance abnormal signaling activity when applied to cells with Ras mutations.
A team of researchers has identified a previously unknown non-coding RNA, called BANCR, that plays an important role in the biology of melanoma. By analyzing the RNA transcriptome of patient samples, they found that BANCR is required for full migratory capacity in melanoma and could be a potential target for therapy.
A study published in Nature Genetics found a correlation between eye color and the risk of developing certain serious skin conditions. People with blue eyes were less likely to have vitiligo, while those with brown eyes may be at lower risk for melanoma.
Researchers developed a new approach using billions of clones of patients' own tumor-fighting cells combined with chemotherapy, showing promise in treating advanced melanoma. The treatment resulted in long-term remission and temporary non-progression of disease in some patients.
Researchers at Sanford-Burnham identified a molecular switch, controlled by protein kinase C-epsilon, that enables melanoma cells to resist chemotherapy. High levels of PKC-epsilon in melanoma are associated with poor prognosis and increased tumor-promoting activity.
A collaboration between researchers has shown that cell senescence occurs spontaneously in melanoma cells but does not stop their growth, which is sustained by a small population of cancer stem cells. The study explains why inducing senescence alone is difficult to treat cancer cells.
Researchers found that imiquimod converts plasmacytoid DCs into tumor-killing effector cells, clearing tumors in a mouse model of melanoma. This discovery has implications for antitumor therapies targeting both skin cancers and other types.
Researchers at Moffitt Cancer Center found that fibroblasts play a significant role in melanoma tumor growth and progression. The study also revealed that fibroblasts contribute to drug resistance and the 'flare' response, where tumors exhibit enhanced metabolism after targeted therapy is stopped.
Researchers from UCLA's cancer and stem cell centers have successfully engineered blood stem cells to create cancer-killing T-cells that seek out and attack human melanoma. The approach could lead to a sustained immune response, potentially protecting against cancer recurrence.
A team of UNC scientists has identified P-Rex1 protein as a crucial factor in the movement of melanoblasts, leading to melanoma development. The study found that mice lacking this protein are resistant to melanoma metastasis, suggesting P-Rex1 plays an important role in cancer spread.
Researchers identified a novel gene mutation in the MITF gene that increases the risk of both inherited and sporadic cases of malignant melanoma. The mutation, known as E318K, was found to block sumoylation of MITF, leading to overactivity and significantly increasing melanoma risk.
Researchers have found that sildenafil, the active ingredient in Viagra, can neutralize chronic inflammation caused by malignant melanoma, allowing tumor-specific T cells to function properly. This study suggests that Viagra may improve treatment results for people with melanoma by boosting antitumor immunity.
Researchers have created melanocytes from mouse tail cells using inducible pluripotent stem cells, offering potential benefits for tissue transplantation, cancer treatment, and drug discovery. The lab-made cells can be studied to understand the development of conditions like vitiligo and melanoma.
The study combines genetic data with mathematical modelling to provide insights into cell differentiation. The findings demonstrate the utility of a systems biology approach, which could have implications for understanding and treating diseases such as cancers caused by abnormal cell function.
Scientists at Tufts University have successfully used cellular laser microsurgery to track the migration and regeneration of melanocytes in a live organism. The technique could lead to new research avenues in wound repair, regenerative medicine, and cancer studies.
Researchers at URMC discovered a receptor called GPR56 that plays an important role in cancer progression and may trigger angiogenesis. This discovery could lead to more effective treatments for malignant melanoma by shutting down VEGF production at its source.
The European Commission has approved YERVOY (ipilimumab) for treating adult patients with previously-treated advanced melanoma. The treatment showed long-term survival rates of 46% and 24% at 1 and 2 years, respectively. YERVOY works by stimulating the immune system to recognize and destroy cancer cells.
Researchers at Dana-Farber Cancer Institute found six abnormal genes that are both cancer-causing and metastasis-promoting in melanoma skin cancer. These genes can be used to predict whether human melanoma tumors are likely to spread, enabling doctors to cure the disease by intervening early.
Researchers discovered that specific microRNAs play a crucial role in melanoma metastasis by suppressing the immune system and promoting cell invasion. The study found that these miRNAs can serve as biomarkers for more aggressive tumors, suggesting new therapeutic targets for battling the deadliest form of skin cancer.
A new study found that heart transplant patients are more likely to develop skin cancers, including cutaneous squamous cell carcinoma and melanoma. The incidence increased post-transplant by up to 30-fold, highlighting the need for improved patient education and screening.
Researchers at NYU Langone Health discovered that Wnt signaling, a biological process controlling many processes, is essential for coordinated actions of hair follicle stem cells and melanocyte stem cells. This study suggests manipulating Wnt signaling may be a novel strategy to target graying hair.
Researchers find that melanoma cells can develop an invasive phenotype when exposed to anti-melanoma drugs, leading to relapse. Blocking CCL2 or its upstream effectors may represent a novel therapeutic approach.